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Abstract
Background and Aims: Patients on home parenteral nutrition (HPN) are at risk for catheter-related complications; mainly
infections and occlusions. We have previously shown in HPN patients presenting with catheter sepsis that catheter locking
with taurolidine dramatically reduced re-infections when compared with heparin. Our HPN population therefore switched
from heparin to taurolidine in 2008. The aim of the present study was to compare long-term effects of this catheter lock
strategy on the occurrence of catheter-related bloodstream infections and occlusions in HPN patients.
Methods: Data of catheter-related complications were retrospectively collected from 212 patients who received HPN
between January 2000 and November 2011, comprising 545 and 200 catheters during catheter lock therapy with heparin
and taurolidine, respectively. We evaluated catheter-related bloodstream infection and occlusion incidence rates using
Poisson-normal regression analysis. Incidence rate ratios were calculated by dividing incidence rates of heparin by those of
taurolidine, adjusting for underlying disease, use of anticoagulants or immune suppressives, frequency of HPN/fluid
administration, composition of infusion fluids, and duration of HPN/fluid use before catheter creation.
Results: Bloodstream infection incidence rates were 1.1/year for heparin and 0.2/year for taurolidine locked catheters.
Occlusion incidence rates were 0.2/year for heparin and 0.1/year for taurolidine locked catheters. Adjusted incidence ratios
of heparin compared to taurolidine were 5.9 (95% confidence interval, 3.9–8.7) for bloodstream infections and 1.9 (95%
confidence interval, 1.1–3.1) for occlusions.
Conclusions: Given that no other procedural changes than the catheter lock strategy were implemented during the
observation period, these data strongly suggest that taurolidine decreases catheter-related bloodstream infections and
occlusions in HPN patients compared with heparin.
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Introduction
Catheter-related bloodstream infections (CRBSIs) remain the
major, potentially life-threatening, complication of home paren-
teral nutrition (HPN) therapy. As such, CRBSIs pose a massive
burden on the patients’quality of life and hospital resources due to
the frequent need for hospital admission, surgical and medical
interventions and, eventually, the need for intestinal transplanta-
tion when venous access becomes irreversibly compromised [1].
Patient-, therapy- and device-related risk factors for CRBSIs
have been characterized previously in detail [2]. The nature of the
underlying disease leading to intestinal failure may increase the
risk of CRBSI [3]. Also factors that are related to the composition
of the parenteral nutrition formulation, such as caloric content and
the presence of a lipid emulsion play a role [4], as well as the
frequency and duration of the use of the venous access device [5].
The presence of a venous access device that bypasses the natural
host barriers by directly connecting the external environment to
the patients’ central bloodstream, has been identified as an
independent risk factor for the occurrence of CRBSIs [6]. The
magnitude of the risk also depends on catheter material [5], site of
catheter insertion [7], and catheter coating [8]. Finally, the agent
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that is used to lock the central venous catheter (CVC) after
infusion of the parenteral nutrition is increasingly being recognized
as pivotal in the prevention of CRBSIs [9].
Several lock solutions, some of which include (combinations of)
anticoagulants, fibrinolytic agents, antiseptics and antibiotics, have
been introduced, but failed because of side effects, microbial
resistance issues or lack in effectiveness [10]. Taurolidine, a
microbiocidal agent, has a broad spectrum activity against bacteria
and fungi [11]. The suggested microbiocidal activity of taurolidine
involves a chemical interaction with the microbial cell wall
resulting in irreparable injury [12]. Taurolidine has shown to
reduce the risk for CRBSIs in several patient groups who depend
on a reliable central venous access device [9,13–19]. A recent
meta-analysis confirms these beneficial effects, but also emphasizes
low power and methodological flaws of the currently available
studies [20].
A randomized trial in our own tertiary HPN referral center
comparing the catheter lock strategy using 2% taurolidine
(Taurosept) and low dose (150 U/mL) heparin on the recurrence
of CRBSIs was preliminary terminated due to the dramatic
decrease in CRBSIs in taurolidine locked catheters that became
apparent because of the open label character of this study [9].
Although the sample size of this formal randomized trial was very
low (heparin: n = 14), taurolidine (n = 16), we considered the
results evident enough to switch from low dose heparin to 2%
taurolidine catheter locking in all of our HPN patients in the fall of
2008. In the present study, we provide further evidence that
taurolidine may be more effective in preventing catheter-related
complications in HPN patients compared to heparin, using a
comprehensive dataset of long-term catheter locking, covering the
period from 2000 to late 2008 (using low-dose heparin) and the
period from 2008 to 2011 (using taurolidine). The study comprises
212 patients, 745 central venous catheters and more than 200,000
catheter days, and provides by far the most robust dataset in this
field so far. Importantly, none of our HPN practice procedures or
materials, other than the catheter lock strategy, changed during
the complete observation period.
Patients and Methods
Ethics
The research ethics committee of the Radboud University
Nijmegen Medical Centre (CMO Regio Arnhem-Nijmegen)
approved this retrospective study under the protocol number
(CMO: 2014/167). This ethics committee confirmed that individ-
ual written informed consent was not needed. Data was collected,
anonymized and de-identified by the treating physician (GW).
Subsequently data were entered in a database and statistical
analysis was performed.
Patients
We enrolled all consecutive patients on long-term (.3 months
and .1/week used for HPN/fluid administration) HPN or fluids
using a central venous catheter (Hickman or Port-A-Cath (PAC,
implantable port)) at the Radboud University Medical Centre,
Nijmegen, the Netherlands, between January 1st, 2000 and
November 1st, 2011 (n= 212). Medical records of all patients
were reviewed. Patients were categorized into one of five
underlying disease groups, based on the indication for fluid/
HPN treatment: motility disorder, short bowel with stoma, short
bowel without stoma, impaired intestinal absorption (mainly due
to radiation enteritis), or other. Data on time and site of catheter
insertion were checked in operation reports.
Cleaning protocol of catheter
Only single lumen catheters were placed. During the observa-
tion period of this study, none of our cleaning protocol procedures
changed. In general, patients are trained in procedures including
catheter handling and HPN/fluid administration during an
inpatient training period of 1 to 2 weeks in our hospital.
Independent of the access type, the patient’s or care-givers’s
hands are washed and subsequently disinfected with chlorhexidine
in ethanol prior to HPN/fluid administration or cleaning of the
exit site or skin. Cleaning protocols for Hickman catheter and
PAC in our hospital are described in more detail in the following
text.
For Hickman catheters, the catheter exit site is covered direct
after catheter insertion with a Tegaderm pad (3M Health Care,
Neuss, Germany) which is replaced every 96 hours. The exit site is
disinfected by circular movements from the exit site to the outer
circumference. Every circle is disinfected with a new sterile swap.
The first 10 centimeters of the catheter is disinfected with a sterile
swap and chlorhexidine in ethanol. After drying, the exit site is
covered with a new Tegaderm pad. After 3 weeks, the catheter cuff
has grown in the surrounding tissues and sutures for line fixation
are removed. From then on, the exit site is no longer covered with
a Tegaderm pad and is cleaned daily by washing with water and
soap and drying with a clean towel.
For PACs, after placement the wound is covered with sterile
compresses. Before HPN/fluid administration, the skin overlying
the subcutaneous port is cleaned with chlorhexidine by the
described circular movement method above. After HPN admin-
istration, the puncture-site is covered with a sterile compress for a
few minutes, until (minor) bleeding ends.
Catheter lock solution
Central venous catheters were locked after every administration
of HPN or fluids. After a successful open label randomized
controlled trial [9], all HPN patients with a Hickman or PAC
switched from low dose (150 U/mL) heparin to 2% taurolidine
(Taurosept) in 2008. Of every individual patient the date of
switching from heparin to taurolidine was used for data analysis.
In case a catheter was locked with heparin and subsequently
with taurolidine, only the period before starting taurolidine was
analyzed, since catheter related complications after start of
taurolidine could possibly be a consequence of a carry-over effect
of locking with heparin, since a biofilm that originated from the
heparin period might lead to a CRBSI in the taurolidine period. In
that case, the total number of catheter days was calculated from
insertion of the catheter to the starting date of the catheter lock
solution taurolidine (Figure 1).
Catheter related bloodstream infections and occlusions
CRBSIs were defined by the presence of symptoms (fever, chills)
associated with positive blood cultures (blood drawn from
peripheral vein and/or from venous access device) in the absence
of other evident infectious foci that likely could explain the
bloodstream infection. Episodes with fever and/or chills without
positive blood cultures were only considered a bloodstream
infection in case blood samples were drawn under antibiotic
treatment (possibly leading to negative blood cultures) and in case
patients were showing signs of sepsis [5]. The date of the CRBSI
was the date of the first positive blood culture. A CRBSI was
considered polymicrobial when different pathogens were found in
the peripheral and/or venous access blood culture. All pathogens,
were classified as Gram positive or Gram negative bacteria or
yeast.
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Catheter occlusions were defined by an obstruction of the
central venous catheter, described in the medical record, or a
vascular occlusion of more than 50% of a vein near the insertion
side of the central venous catheter, described in report of a duplex
scan. The date of occlusion was the date of the first time that this
occlusion was described.
Treatment
Data on the use of anticoagulants and immune suppressive
medication, and the type of HPN/fluid formulation and the
frequency of HPN/fluid administrations per week was obtained
from pharmacy prescriptions. Catheters were described as
catheters which were exposed to only fluids, only HPN or a
combination of both.
Hospital admission
We evaluated hospital admission data in the pre (2006–2007)
and post (2009–2011) taurolidine eras. The transition year 2008
included hospital admissions with taurolidine and heparin locked
catheters. No detailed hospital admission data were available of
the period before 2006. All hospital admissions for in-hospital
training of aseptic catheter techniques were excluded from
analysis, since these admissions were not due to complications.
Hospital admission were presented as the days that the patients
were admitted to our ward in one year divided by the total number
of catheter days in that year.
Adverse events
Adverse events resulting in discontinuation of the use of
taurolidine were reported. If possible, patients switched first to
another taurolidine-containing lock in the form of taurolidine-
citrate (Taurolock) and in case of repeated adverse effects switched
to saline.
Statistical analysis
Characteristics of patients, vascular accesses and CRBSIs were
presented as number (n) with percentage (%), or mean with 95%
confidence interval (CI), or median with 25th and 75th percentile.
Chi-square test for categorical data and Mann Whitney U test for
continuous data were used to compare the heparin and taurolidine
Figure 1. Flowchart of numbers of patients and catheters.
doi:10.1371/journal.pone.0111216.g001
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group in Table 1 and 2. Statistical significance was accepted if the
probability of a type I error did not exceed 5%. We analyzed
incidence rates and incidence rate ratios (i.e., the complication
incidence rate that occurred with catheters locked with heparin
divided by those locked with taurolidine) of CRBSIs and
occlusions using random effects model with Poisson distributions
for counts. Random effects for patients were incorporated in the
modeling process to account for repeated vascular access periods
within a patient. Possible confounders in the relation between
catheter lock solution and complication rate were identified and
reported, based on biological and clinical rationales [5], or a
change of 10% or more on unadjusted complication rate ratios by
a covariate. Adjusted complication incidence rate ratios for
heparin over taurolidine were calculated with respect to these
confounders. The NLMIXED procedure of SAS System for
Windows version 9.2 was used (SAS Institute Inc, Cary, NC).
Statistical significance was accepted if the probability of a type I
error did not exceed 5%. To provide information about statistical
significance, we reported 95% CI where appropriate. In case data
were missing from medical records these were considered to be
completely at random and were excluded from analyses.
Results
Study population
212 HPN patients were included in the study: 62 patients had
multiple catheters that were initially locked with heparin and later
catheters that were locked with taurolidine, 105 patients had
catheters that were exclusively locked with heparin, and 45
patients had their catheters exclusively locked with taurolidine
(Figure 1). Most patients were male (n (%): 102 (61%) and 74
(69%) in heparin and taurolidine group, respectively). Patients
started HPN at a mean (95% CI) age of 48 years (18–78 years) in
the heparin group and 49 years (22–77 years) in the taurolidine
group. The major indications for HPN (n (%)) use were motility
disorder and short bowel syndrome with or without a stoma; 46
(28%), 32 (19%) and 69 (41%) patients in the heparin group, and
40 (37%), 28 (26%) and 34 (32%) patients in the taurolidine group,
respectively. Less common indication of HPN was impaired
intestinal absorption; 9 (5%) and 4 (4%) patients in the heparin
and taurolidine group, respectively. All remaining patients were
classified as other HPN indication (n (%)); 11 (7%) patients with
heparin locked catheters and 1 (1%) patient with taurolidine
locked catheters. The majority of patients (n (%)) was trained at
our tertiary referral centre in aseptic catheter handling and
parenteral nutrition administration; this concerned 143 (86%)
patients for the heparin and 83 (78%) patients for the taurolidine
group.
Vascular accesses
The characteristics of a total of 745 central venous catheters, of
which 545 were locked with heparin and 200 with taurolidine were
included (Figure 1) and analyzed (Table 1). In both groups
Hickman catheters (about 70%) were used more frequently than
PACs (about 30%). Around 75% of the catheters were inserted in
the jugular or subclavian veins; in the heparin group the
subclavian vein (62%) was the most common insertion place,
while in the taurolidine group the jugular vein (52%) was mostly
used. Catheter survival (days: median (25th–75th percentile)) was
longer in the taurolidine group (209 days (65–611 days)) compared
to the heparin group (120 days (43–310 days)). The total number
of catheter days was 147,842 for the 545 heparin locked catheters
and 71,112 for the 200 taurolidine locked catheters. Patients with
catheters in the taurolidine group were more experienced in the
administration of HPN/fluids (probably a consequence of having
had heparin locked catheters before), since the median (25th–75th
percentile) duration from the start of HPN/fluid use to the
creation of the venous access was longer; 214 days (34–765 days)
for the heparin group and 564 days (103–1489 days) for the
taurolidine group. Most catheters were used more than 5 days a
week (75% and 71%, in the heparin and taurolidine group,
respectively). HPN only was administered in 53% and 59%, in the
heparin and taurolidine group, respectively, whilst a combination
of HPN and fluids was administered in 32% and 31%,
respectively. A minority, 6% of heparin and 8% of taurolidine
catheters, was used for fluid administration only. Half of the
catheters (53% and 55% in heparin and taurolidine group,
respectively) were inserted in patients who used anticoagulants,
and less than a quarter (15% and 21% in heparin and taurolidine
group, respectively) of the catheters were inserted in patients who
used immune suppressive medication.
Bloodstream infections and occlusion incidence rates
CRBSIs were 464 and 43 times detected in heparin and
taurolidine locked catheters, respectively. Table 2 presents the
characteristics of these CRBSIs. Forty-four percent of CRBSIs had
both a positive blood culture of peripheral and venous access
origin. The majority of CRBSIs (74 and 65% in heparin and
taurolidine group, respectively) was based on a single type of
pathogen. The most common microbial species that caused these
CRBSIs were Gram-positive bacteria, followed by Gram-negative
bacteria and fungi.
Table 3 shows the unadjusted incidence rates and the adjusted
(for confounders) incidence rate ratios of heparin over taurolidine.
Bloodstream infection incidence rates (per access year (95% CI))
were 1.1 per access year (0.9–1.3 per access year) in the heparin
group and 0.2 per access year (0.1–0.2 per access year) in the
taurolidine group. The bloodstream infection incidence ratio, of
heparin compared to taurolidine incidence rates, adjusted for
confounders (underlying disease, anticoagulant use, immune
suppressive use, HPN/fluid frequency per week, composition of
infusional fluid, place of catheter insertion and HPN/fluid use
before creation catheter), was 5.9 (95% CI, 3.9–8.7).
Catheter related vascular occlusions were 137 and 34 times
detected in heparin and taurolidine locked central venous
catheters, respectively. As presented in Table 3, occlusion rates
(per access year (95% CI)) were slightly lower in the taurolidine
group (0.1 per access year (0.1–0.2 per access year)) compared to
the heparin group (0.2 per access year (0.2–0.3 per access year)).
The occlusion incidence ratio, of heparin compared to taurolidine
incidence rates, adjusted for confounders (underlying disease,
anticoagulant use, immune suppressive use, HPN/fluid frequency
per week, composition of infusional fluid, place of catheter
insertion and HPN/fluid use before creation catheter), was 1.9
(95% CI, 1.1–3.1).
Hospital admissions
From 2006 towards the end of 2011 the number of HPN-related
admission days at our 15-bed clinical ward remained stable at a
mean (6 SD) of 11736159 days per year, while the HPN
population increased from 61 to 133 patients, hence the number of
catheter days increased from 21,619 to 45,960. Therefore, the
ratio of hospital admission days per catheter day decreased by
60% from 0.055 in two pre-taurolidine years to 0.022 in 2011
(Figure 2).
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Adverse events
Since the switch from heparin to taurolidine 8 of the 107
patients reported adverse events possibly related to use of
taurolidine, and did not continue using pure taurolidine as a
result. One patient experienced an anaphylactic-like reaction
(vomiting, shortness of breath and urticaria) within minutes after
the first administration and switched to saline for catheter locking.
Five patients, who experienced a burning sensation, PAC
occlusion, dizziness, nausea or pain and paresthesia, switched first
to taurolidine-citrate, but experienced similar adverse reactions
and switched thereafter successfully to saline. Two patients who
experienced palpitations or discomfort over the chest switched
successfully to taurolidine-citrate.
Table 1. Vascular access characteristics.
Heparin (n =545) Taurolidine (n =200) p-value
Duration of HPN/fluid use before creation catheter (days: median (25th–75th
percentile))
214 (34–765) 564 (103–1489) 0.000*
Unknown (n (%)) 7 (1) 0 (0)
Type of vascular access (n (%)) 0.536
Hickman 368 (68) 140 (70)
Port a` cath 177 (32) 60 (30)
Place of catheter insertion (n (%)) 0.000*
Subclavian vein 337 (62) 57 (29)
Jugular vein 63 (12) 105 (52)
Femoral vein 33 (6) 19 (9)
Inferior caval vein 13 (2) 6 (3)
Unknown 99 (18) 13 (7)
Catheter survival (days) 0.000*
Median (25th–75th percentile) 120 (43–310) 209 (65–611)
Total number of catheter days of all catheters 147,842 71,112
Number of catheters still in place (n (%)) 0.000*
Yes 1 (0) 80 (40)
No 544 (100) 120 (60)
Composition of infusional fluid (n (%)) 0.380
HPN alone 290 (53) 118 (59)
Fluid alone 30 (6) 16 (8)
HPN & fluid 178 (32) 61 (31)
Unknown 47 (9) 5 (2)
HPN/fluid administration frequency, per week (n (%)) 0.529
1 3 (1) 1 (1)
2 5 (1) 4 (2)
3 32 (6) 14 (7)
4 34 (6) 18 (9)
5 50 (9) 21 (11)
6 44 (8) 11 (5)
7 319 (58) 111 (55)
Unknown 58 (11) 20 (10)
Immune suppressive use (n (%)) 0.121
Yes 83 (15) 41 (21)
No 437 (80) 154 (77)
Unknown 25 (5) 5 (2)
Anticoagulant use (n (%)) 0.932
Yes 288 (53) 111 (55)
No 220 (40) 83 (42)
Unknown 37 (7) 6 (3)
Variables are shown per vascular access. Patients may have had multiple vascular accesses, total number of patients assessed is 212 (Figure 1). Characteristics were
presented as number of events (n) with percentage (%) or median with 25th and 75th percentile. A p-value lower than 0.05 was considered statistically significant.
doi:10.1371/journal.pone.0111216.t001
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Discussion
The availability and maintenance of an adequate and reliable
venous access remains the foremost worry in long-term HPN care,
with catheter related complications, mainly infections and
occlusions, causing the majority of problems. This study presents
by far the most robust data set so far to demonstrate that the use of
taurolidine as catheter lock versus low-dose heparin decreases
catheter related complications. During an observation period
spanning over 200,000 catheter days, we found an impressive six
times higher chance of developing CRBSI in heparin compared to
taurolidine locked catheters. Also, a two times higher risk for
developing catheter occlusions in heparin locked compared to
taurolidine locked catheters was observed. Interestingly, we saw
that this decrease in catheter complications was accompanied by a
steep decrease in strain on healthcare resources in the form of
diminished hospital admissions. Importantly, none of our other
HPN-related procedures or techniques changed during this period
suggesting that the type of catheter lock was instrumental in these
observations.
The observed effectiveness of taurolidine to prevent CRBSI
found in our study is in agreement with previous research in
various patient populations [9,21–25]. A meta-analysis including
six studies covering 86,000 catheter days found a slightly lower
Table 2. Characteristics of catheter related bloodstream infections.
Heparin Taurolidine p-value
Origin positive blood cultures (n (%)) 0.000*
Peripheral 34 (7) 15 (35)
Catheter 217 (47) 9 (21)
Both 206 (44) 19 (44)
Unknown 6 (1) 0 (0)
Type of bloodstream infection (n (%)) 0.147
Monomicrobial 345 (74) 28 (65)
Polymicrobial 113 (24) 15 (35)
Unknown 6 (2) 0 (0)
Type of pathogens in peripheral blood culture (n (%))** 0.093
Gram positive bacteria 164 (57) 24 (55)
Gram negative bacteria 94 (32) 11 (25)
Yeast 26 (9) 9 (20)
Unknown 6 (2) 0 (0)
Type of pathogens in catheter blood culture (n (%))** 0.332
Gram positive bacteria 313 (55) 24 (57)
Gram negative bacteria 209 (37) 12 (29)
Yeast 43 (7) 6 (14)
Unknown 6 (1) 0 (0)
Characteristics were presented as number of events (n) with percentage (%). *A p-value lower than 0.05 was considered statistically significant. **More pathogens than
CRBSI, because of polymicrobial infections and differences in positive blood cultures between blood cultures of peripheral and venous access origin.
doi:10.1371/journal.pone.0111216.t002
Table 3. Catheter related bloodstream infection and occlusion incidence rates and incidence rate ratios in heparin and taurolidine
locked catheters.
Incidence rate per access year (95% CI) Adjusted incidence rate ratio (95% CI)*
Catheter related bloodstream infection
Heparin 1.1 (0.9–1.3)
Taurolidine 0.2 (0.1–0.2)
Heparin/taurolidine ratio 5.9 (3.9–8.7)
Catheter related occlusion
Heparin 0.2 (0.2–0.3)
Taurolidine 0.1 (0.1–0.2)
Heparin/taurolidine ratio 1.9 (1.1–3.1)
Data were analyzed using random effects model with Poisson distributions for counts. *Adjusted values are corrected for: underlying disease, anticoagulant use, immune
suppressiveuse,HPN/fluid frequencyperweek, compositionof infusional fluid, anddurationofHPN/fluidusebeforecreationcatheter.Randomeffects forpatientswere incorporated
to account for repeated vascular access periods within a patient.
doi:10.1371/journal.pone.0111216.t003
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than our study, but still an impressive three times (confidence
interval: 1.8–4.8) higher risk for the development of CRBSI in
CVCs locked with heparin compared to taurolidine. Due to small
sample sizes as well as methodological deficiencies of the included
studies in the meta-analysis these results should be interpreted with
caution [20]. Also because these studies contain different
heterogeneous patient populations with distinct risk profiles for
the development of CRBSIs, and because the effects of diverse
taurolidine containing lock solutions, which differ in taurolidine
concentration and the presence of other agents such as citrate
and/or heparin, were pooled. Concerning the latter, minor
differences between extremely diluted pure taurolidine and
taurolidine-citrate(-heparin) solutions in the inhibition of growth
of yeast, Gram negative and Gram positive bacteria in vitro have
been found. The clinical relevance of these minor differences
between different taurolidine solutions remains however unclear in
the absence of clinical comparative studies [26].
Although taurolidine has shown to be able to decrease thrombus
weight, but is not as effective as heparin in this respect [27], we
observed a lowered incidence of catheter related occlusions with its
use. Previous studies described a relationship between the number
of CRBSI and occlusions, possibly due to infection-induced
activation of the coagulation system [28]. In the same vein, the
decrease in catheter related occlusions in our study may be the
result of diminished vascular damage because of the lower
infection rate [28]. In contrast, the earlier mentioned meta-
analysis (with its described limitations) found no significant
difference between taurolidine and heparin-treated CVCs in
incidence of catheter occlusions [20].
The sharp decrease in catheter related complications that we
observed after switching from catheter locking with heparin to
taurolidine had a highly significant impact on the clinical burden
that HPN care imposes on our clinical ward, as proven by the
sharp decrease in number of days that HPN patients spent within
the hospital. Keeping in mind that in Europe in general the cost of
each case of catheter infection lies between 4,000 to 13,000 Euros
[29], and the costs in the Netherlands for one year taurolidine
locking (1,800 Euro per year) are about 300 Euros more than for
heparin locking (1,500 Euro per year), taurolidine seems from a
financial point of view promising. Still, a formal cost-effectiveness
analysis is necessary to confirm that taurolidine is cost-effective.
In our study, approximately 7 percent of all patients who locked
their catheter with taurolidine experienced (mostly mild) side
effects, that urged us to stop the use of (any) taurolidine or switch
to a different taurolidine formulation. This switch mostly resulted
in similar side effects after which the patient used saline as a
catheter lock. Only one probable anaphylactic reaction was
observed and we did not dare to rechallenge this patient with the
same or another taurolidine preparation. Although theoretically
anaphylaxis seems unlikely due to the metabolization of
taurolidine into taurine and carbon dioxide, other constituents
such as polyvinylpyrrolidone (PVP-17), that is used as a
stabilisator/emulgator, might cause these problems, as described
in a case study [30]. Side effects have been described before for
taurolidine with citrate in a paediatric patient population with
haematological malignancies. Twenty percent of the paediatric
patients had side effects ranging from discomfort in chest and
neck, perioral dysaesthesia, abnormal taste sensations to nausea,
and half of these patients using the lock solution taurolidine with
citrate was urged to stop with these lock solution because of the
side effects they experienced [22].
The statistical significant differences between the taurolidine
and heparin locked catheters in HPN/fluid use before the creation
of the catheter and the vascular acces in situ duration (Table 1) are
a direct consequence of the fact that 62 of the 212 patients first
locked their catheters with heparin and subsequently locked with
taurolidine (Figure 1). The number of catheters that are still in situ
are significantly higher in the taurolidine group (Table 1),
primarily because the HPN population switched to taurolidine
and none of the catheters were locked with heparin at the end of
this study.
The place of catheter insertion is significantly different between
the two groups. However, the place of insertion is dependent of
different factors. The choice of venous access depends on the
estimated length of parenteral nutrition dependency, the condition
of the veins and the personal preference of the patient, with respect
to esthetics (visibility of access device) and need for (self-
)puncturing. Patients who have had more complications, may
have less options left for venous access. A comparison between the
place of insertion between catheters locked with taurolidine and
heparin is therefore difficult. A recent systematic review did find
similar risks for catheter-related complications in subclavian and
internal jugular central venous catheters [31].
A significant difference was found in the origin of positive blood
cultures between heparin and taurolidine locked catheters
(Table 2). We could not explain these differences. When we
compare the type of pathogens that caused the CRBSI in the
heparin and the taurolidine locked catheters (Table 2), it is
interestingly to observe that in taurolidine locked catheters a
higher percentage of the CRBSIs is caused by yeasts. This might
theoretically be a consequence of the fact that yeast are less
sensitive to taurolidine, since in vitro studies showed that higher
taurolidine concentrations are necessary to eliminate yeasts
compared to bacteria [11].
The results of the statistical analysis in Table 1 and 2 should be
interpreted with care, since the variables were not corrected for
overrepresentation of patients who had multiple vascular accesses.
To control for overrepresentation of certain patients, we used a
specific statistical model that accounts for repeated measurements
in the Poisson analysis, presented in Table 3. Variables of Table 1
and 2 were added as a covariate in the Poisson analysis, based on
biological and clinical rationales, or based on the fact that the
covariate changed the unadjusted complication rate ratios with
10% or more.
Figure 2. Hospital admissions in period 2006 until 2011.
Catheters were locked with heparin (2006–2007) and taurolidine
(2009–2011). In 2008 admissions of both lock strategies were included.
Data are presented as the days that the patients were admitted to our
ward divided by the total number of catheter days.
doi:10.1371/journal.pone.0111216.g002
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The retrospective nature of this study obviously has its pro’s and
con’s. This study setting enabled us to collect and analyze a
substantial number of patients (212), catheters (745) and catheter
days (.200,000) from a single center, which makes this by far the
most extensive study in this field so far, with only a limited amount
of missing data. The downside remains that this study setting
hampers the drawing of any conclusions on causal relations.
A limitation of the study is that the diagnoses was based on the
presence of symptoms (fever, chills) in association with positive
blood cultures and in the absence of other evident infectious foci
that likely could explain such an infection. Because of the
retrospective nature of the study, it was not possible to use the
differential-time-to positivity criteria for diagnoses of CRBSI.
We chose to include all venous accesses of a single patient
instead of only the first, since most long-term HPN patients are
likely to have more than one catheter over, making our approach
more representative for clinical practice. Since none of our other
HPN-related procedures or techniques changed during this
period, except for the locking strategy, we don’t think that bias
was introduced by the fact that the cohorts of heparin and
taurolidine catheters had not the same observation period.
An important remaining question is whether taurolidine should
be used in all HPN patients or only in those who have a high risk
for developing CRBSIs, also in light of the fact that it remains
unclear from our study design whether the difference in infection
rates between both strategies is caused by promotion of infections
by heparin and/or prevention of this problem by taurolidine. We
hope to shed light on this issue in a multicenter randomized
controlled trial that is currently ongoing and which investigates the
effectiveness of taurolidine versus saline in preventing CRBSI
(ClinicalTrials.gov number, NCT01826526).
Despite the limitations of the study, we suggest that the long-
term use of the lock solution taurolidine is more effective in
preventing catheter related bloodstream infections and occlusions
in HPN patients with CVCs than heparin.
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